Skip to main content
European Commission logo print header

Disruptive targeted drug delivery system via synergistic combination of intelligent DNA molecular machines and gated mesoporous nanoparticles

Descripción del proyecto

Una administración selectiva de fármacos gracias a la nanotecnología

Los fármacos quimioterapéuticos se caracterizan por provocar efectos colaterales en tejidos sanos y, a menudo, una menor biodistribución en el tumor. El equipo del proyecto SMARTRIOX, financiado con fondos europeos, ha desarrollado un sistema basado en nanopartículas que puede programarse para administrar el fármaco necesario a su diana. Esta especificidad se basa en moléculas de ADN que responden a ciertos estímulos en los tejidos diana y administran el fármaco. Los investigadores emplearán este sistema contra el cáncer de mama triple negativo, una variante agresiva y difícil de tratar. Su principal ventaja es que puede adaptarse a las necesidades de cada paciente en el hospital, lo cual lo convierte en un medio de administración de fármacos fácilmente accesible.

Objetivo

Although there are Triple Negative Breast Cancer (TNBC), the most aggressive type of Breast Cancer (BC), accounts for 15-25% of all BCs. Yearly 200,000 women are diagnosed with TNBC, of which 100,000 are diagnosed with metastatic disease at the primary diagnosis. TNBC lacks a recognized molecular target, making it an orphan disease: no effective treatment is available to date. The poor prognosis of patients suffering from TNBC makes it extremely challenging for both oncologists and patients. TNBC is more aggressive because all its receptors (Estrogen/Progesterone/Herceptin) are negative, and targeted and endocrine therapies are not helpful. TNBC shows a shortened disease-free interval in the neoadjuvant and adjuvant settings and a more aggressive course in the metastatic setting.The mainstay treatment for TNBC is Doxorubicin, a potent anthracycline chemotherapy, which nonetheless, has substantial toxicities (cardiac, immune, digestive and epithelial) that limit its maximal dose and render the tumour cells resistant to it. As a result, patients cannot be treated with a high enough and effective dose.In response, Triox Nano has developed TXN770: an innovative bionanoparticle based anticancer treatment. TXN770 has a DNAzyme machine cap that recognizes cancer cells and releases the chemotherapy exclusively inside them, responding to pre-programmed threshold levels of Mg2+ and ATP that are present primarily at the target TNBC cells. This allows using 4 times lower concentrations of Doxorubicin, which in turn causes less side effects and achieves a higher effectiveness. It also prevents cancer cells from becoming resistant to Doxorubicin.TrioxNano will address a BC world market of $10.4 billion, expected to grow to $17.2 billion in 2021. TrioxNano projects €547M in profit, with a ROI of €15 per euro invested in the project and in turn will help ease the economic burden of TNBC in National Health Services while positioning itself as a leading company in treatment of TNBC.

Convocatoria de propuestas

H2020-EIC-SMEInst-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEInst-2018-2020-2

Régimen de financiación

SME-2 - SME instrument phase 2
æ

Coordinador

TRIOX NANO LTD
Aportación neta de la UEn
€ 1 993 367,25
Dirección
Rokach shimon 4
9518705 Jerusalem
Israel

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Otras fuentes de financiación
€ 854 300,25